LEXX · Lexaria Bioscience Corp. · Proposed Sales
$2.65
+0.05 (+1.92%)
At close · Oct 20
View the 10-Q filed Jul 13, 2026
Return incl. dividend (before tax)
Going-concern doubt
— flagged Jul 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The recurring losses and negative net cash flows raise substantial doubt as to the Company's ability to continue as a going concern. However, we have also concluded that our existing cash, combined with inflows expected from executed license agreements, will not be sufficient to meet the Company's financial obligations for the twelve-month period following the issuance of these consolidated financial statements. Accordingly, there is substantial doubt as to our ability to continue as a going concern within one year from the date of issuance of these financial statements.”View the 10-Q filed Jul 13, 2026
Customer concentration
— top customer 100% of revenue
One customer — 100% of revenue (the nine months ended May 31, 2026)
“In the nine months ended May 31, 2026, the Company recognized revenue of $20,000 on a consolidated basis. One customer accounted for 100% of that total.”
2 customers — 100% of revenue (the nine months ended May 31, 2025)
“In the nine months ended May 31, 2025, the Company recognized revenue of $531,923 on a consolidated basis. Two customers accounted for 100% of that total.”
Market Cap
$4.38M
Shares
1.65M
Volume · Oct 20
42.02K
Avg daily vol (56 sessions)
82.01K
Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.
No Proposed Sales
No Form 144 proposed-sale notices are available for this stock yet.